- Home
- ABVX vs QGEN Comparison
ABVX vs QGEN Comparison
Compare ABVX & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ABVX | QGEN |
|---|---|---|
| Founded | 2013 | 1986 |
| Country | France | Netherlands |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 10.2B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ABVX | QGEN |
|---|---|---|
| Price | $114.15 | $48.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 6 |
| Target Price | ★ $118.33 | $50.20 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 08-11-2025 | 02-04-2026 |
| Dividend Yield | N/A | ★ 3.36% |
| EPS Growth | N/A | ★ 331.20 |
| EPS | N/A | ★ 1.94 |
| Revenue | $6,231,374.00 | ★ $2,070,781,000.00 |
| Revenue This Year | $6.80 | $7.07 |
| Revenue Next Year | N/A | $6.14 |
| P/E Ratio | ★ N/A | $25.73 |
| Revenue Growth | N/A | ★ 5.32 |
| 52 Week Low | $4.77 | $39.61 |
| 52 Week High | $148.83 | $54.61 |
Technical Indicators
Market Signals| Indicator | ABVX | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 43.25 | 67.82 |
| Support Level | $116.20 | $44.71 |
| Resistance Level | $129.56 | $46.02 |
| Average True Range (ATR) | 7.87 | 0.76 |
| MACD | -2.47 | 0.30 |
| Stochastic Oscillator | 15.05 | 80.70 |
Price Performance
Historical ComparisonAbout ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).